摘要
回顾性分析PET(Paclitaxel 135 mg/m2,d1,Vp-16 75 mg/m2 d1～d3,DDP 80 mg/m2,d1～d3使用)方案化疗联合胸部放疗治疗局限期小细胞肺癌的临床疗效.24例局限期小细胞肺癌接受PET化疗,每3周重复1次,共4～6个周期,胸部放疗于化疗2个周期后开始进行,2 Gy/(5次·周),Dr50～60 Gy/25～30次,治疗达完全缓解者予以全脑预防性放疗Dr30Gy/(15次·3周).结果显示,24例局限期小细胞肺癌患者完全缓解(CR)19例,部分缓解(PR)4例,总缓解率95.8%(CR79.2%,PR 16.7%),中位生存期25个月,2、3年生存率分别为50.0%和41.7%,局部复发率29.2%,远处转移率54.2%.PET方案化疗联合胸部放疗治疗局限期小细胞肺癌有较好的缓解率和近期疗效,毒性反应可耐受.
To explore the efficacy of PET （Paclitaxel 135 mg/m^2 d1 ,Vp-16 75 mg/m^2 d1-3 ,DDP 80 mg/m^2 over d1-3 ） regimen chemotherpy combined with thoracic radiotherapy for limited small cell lung cancer. 24 patients of limited small cell lung cancer were treated with 4-6 cycles PET regimen, and received thoracic radiotherapy after 2 cycles chemotherapy at 2 Gy/F, once a day, 5 days per week to DT 50-60 Gy/20-30F/5-6W. DT30 Gy/15 F/3 W of prophylactic cranial irradiation was given for complete remission patients after treatment. The overall response rate was 95.8% （CR 79.2%, PR 16.7%）, the MST was 25 month, and the 2-, 3-year survival rates were 50.0%, 41.7% respectively. There was a better response and efficacy of PET regimen chemotherapy combined with thoracic radiotherapy for limited small cell lung cancer. The side effects of PET could be accepted.
出处
《肿瘤防治杂志》
2005年第24期1901-1902,共2页
China Journal of Cancer Prevention and Treatment
关键词
肺肿瘤/药物疗法
肺肿瘤/放射疗法
癌
小细胞
lung neoplasms/drug therapy
lung neoplasms/radiotherapy
carcinoma, small cell
作者简介
马进安，男，湖南石门人，硕士，主治医师，主要从事肿瘤的综合治疗的研究工作。Tel：86-731-5295229 E-mail：majinancs@hotmail．com.
